Pragathi Duggina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pragathi Duggina has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ashoo Grover
Indian Council of Medical Research, New Delhi, India
1 shared publication E. Prabhakar Reddy
CEO & Professor of Biochemistry, Anna Gowri Medical College and Hospital, Parameswaramangalam, Puttur, Tirupati District, Andhra Pradesh, India.
1 shared publication- Hemanth Raj Thangappazham
Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, USA.
1 shared publication - Kumar Guru Mishra
Department of Community Medicine, Apollo Institute of Medical Sciences and Research, Hyderabad, India
1 shared publication - L. Kuladeep Kumar
Babu University, Tirupati, India.
1 shared publication - Nabnita Patnaik
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Bibinagar, India.
1 shared publication
Latest Publications
- Open Access
- 20 February 2025
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 71 (2) , 74-79
Impact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis
Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformins impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatins role as a therapeutic target in PCOS.
- 20 February 2025
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 71 (2) , 74-79
Open AccessImpact of metformin therapy on serum visfatin levels in polycystic ovary syndrome: a systematic review and randomized permuted meta-analysis
Visfatin, an, is associated with reproductive and metabolic disorders like polycystic ovary syndrome (PCOS). Although visfatin levels are known to be elevated in PCOS, the effect of metformin treatment on these levels remains unclear. This meta-analysis aimed to assess changes in circulating visfatin levels before and after metformin intervention in PCOS patients. Relevant studies were identified through comprehensive searches, and a random-effects meta-analysis was conducted to calculate standardized mean differences (SMDs) with 95% confidence intervals (CIs). Sensitivity analysis and randomized permuted meta-analyses (with 1,000, 10,000, and 100,000 iterations) were performed to validate the findings. The analysis included four studies and showed a significant reduction in visfatin levels following metformin treatment (SMD: -0.45, 95% CI: -0.76 to -0.14, p = 0.0043). These results highlight metformins impact on visfatin levels in PCOS, though larger trials are needed to further explore visfatins role as a therapeutic target in PCOS.